A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2015
At a glance
- Drugs Buparlisib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 23 Jan 2013 Status changed from recruiting to discontinued, based on information in Novartis' Form 20-F (http://www.sec.gov/Archives/edgar/data/1114448/000104746913000377/a2212460z20-f.htm).
- 30 Sep 2012 Planned End Date changed from 1 Aug 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 17 Apr 2012 Planned End Date changed from 1 Dec 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.